Allogeneic hematopoietic stem cell transplantation (HSCT) is an important therapy for a variety of cancers, including leukemias, lymphomas, and myeloma. Several complications limit its use, including relapse of malignancy, graft-versus-host disease, and prolonged immune depletion caused by the conditioning required for successful transplantation — all of which can lead to increased morbidity and mortality after allo-HSCT. My laboratory studies clinically relevant problems in HSCT and aims to develop novel therapeutic strategies to improve patient outcome.
Marcel R. M. van den Brink, MD, PhD
Research FocusPhysician-scientist Marcel R. M. van den Brink studies the immunology of bone marrow transplantation with a particular focus on intestinal microbiome and strategies to enhance thymus and immune reconstitution
EducationMD, PhD, Universiteit Leiden
- Velardi E, Tsai JJ, Radtke S, Cooper K, Argyropoulos KV, Shieh JH, Young LF, Lazrak A, Smith OM, Lieberman S, Kreines F, Shono Y, Wertheimer T, Jenq RR, Hanash AM, Narayan P, Lei Z, Moore MA, Kiem HP, van den Brink MRM*, Dudakov JA*. Suppression of luteinizing hormone enhances HSC recovery after hematopoietic injuries. Nature Medicine. 2018; 24(2):239-246. PMC5803436
- Staffas A, Burgos da Silva M, Slingerland AE, Lazrak A, Bare CJ, Holman CD, Docampo MD, Shono Y, Durham B, Pickard AJ, Cross JR, Stein-Thoeringer C, Velardi E, Tsai JJ, Jahn J, Jay H, Lieberman S, Smith OM, Pamer EG, Peled JU, Cohen DE, Jenq RR, van den Brink MRM. Nutritional support from the intestinal microbiota improves hematopoietic reconstitution after bone marrow transplantation in mice. Cell Host & Microbe. 2018; 23(4):447-457. (commentary in Science 2018; 360(6387):394-395 and in Cell Host & Microbe 2018; 23(4):423-424.) PMC5897172